S Barel et al.
Clinical pharmacology and therapeutics, 61(4), 442-449 (1997-04-01)
To investigate the pharmacokinetics of the four stereoisomers of valnoctamide, a mild tranquilizer endowed with anticonvulsant properties. Racemic valnoctamide, 400 mg, was administered orally to seven healthy subjects and to six patients with epilepsy stabilized with long-term carbamazepine therapy. In...
Nina Isoherranen et al.
Pharmaceutical research, 20(8), 1293-1301 (2003-09-02)
Racemic valnoctamide (VCD) is a central nervous system-active drug commercially available in Europe. VCD possesses two chiral centers and, therefore, it exists as a mixture of four stereoisomers. The purpose of this study was to evaluate the anticonvulsant activity of...
Valnoctamide inhibits cytomegalovirus infection in developing brain and attenuates neurobehavioral dysfunctions and brain abnormalities
Ornaghi S, et al.
The Journal of Neuroscience, 37(29), 6877-6893 (2017)
F Pisani et al.
British journal of clinical pharmacology, 34(1), 85-87 (1992-07-01)
The effect of the valpromide isomer valnoctamide (VCD, 200 mg three times daily for 8 days), an over-the-counter tranquillizer, on the elimination kinetics of a single oral dose of carbamazepine-10, 11-epoxide (CBZ-E, 100 mg) was investigated in healthy subjects. During...
A Haj-Yehia et al.
Journal of pharmaceutical sciences, 77(10), 831-834 (1988-10-01)
Valnoctamide (2-ethyl-3-methylpentanamide; VCD), an isomer of valpromide possessing both anxiolytic and antiepileptic properties, has been used as a tranquilizer in the treatment of anxiety and tension. As VCD is an isomer of valpromide (VPD), which is used both as an...